Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation
Inari Medical (NASDAQ: NARI) announced it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The meeting is scheduled for Tuesday, October 29, 2024, at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time. Interested parties can access the live event via the Events Section of the Inari investor relations website. A replay will be available shortly after the event and archived on the website.
Inari Medical (NASDAQ: NARI) ha annunciato che ospiterà un incontro con analisti e investitori per discutere lo studio PEERLESS dopo la sua presentazione nelle Sessioni dei Trial Clinici a Rottura Ritardata al Simposio Scientifico Annuale della Transcatheter Cardiovascular Therapeutics (TCT) a Washington, D.C. L'incontro è programmato per martedì 29 ottobre 2024, alle 11:00 ora del Pacifico / 14:00 ora dell'Est. Le parti interessate possono accedere all'evento live tramite la Sezione Eventi del sito web delle relazioni con gli investitori di Inari. Una registrazione sarà disponibile poco dopo l'evento e archiviata sul sito.
Inari Medical (NASDAQ: NARI) anunció que llevará a cabo una reunión con analistas e inversores para discutir el estudio PEERLESS luego de su presentación en las Sesiones de Ensayos Clínicos de Último Minuto en el Símbolo Científico Anual de Terapias Cardiovasculares Transcatéteres (TCT) en Washington, D.C. La reunión está programada para el martes 29 de octubre de 2024, a las 11:00 a.m. Hora del Pacífico / 2:00 p.m. Hora del Este. Las partes interesadas pueden acceder al evento en vivo a través de la Sección de Eventos del sitio web de relaciones con los inversores de Inari. Una repetición estará disponible poco después del evento y se archivará en el sitio.
이나리 메디컬 (NASDAQ: NARI)는 2024년 트랜스카테터 심혈관 치료법(TCT) 연례 과학 심포지엄에서 임상 시험 발표 이후 PEERLESS 연구에 대해 논의하기 위해 애널리스트 및 투자자 회의를 개최한다고 발표했습니다. 회의는 2024년 10월 29일 화요일 오전 11:00 태평양 표준시 / 오후 2:00 동부 표준시에 예정되어 있습니다. 관심 있는 분들은 이나리 투자자 관계 웹사이트의 이벤트 섹션을 통해 실시간 이벤트에 참석할 수 있습니다. 이벤트 직후 녹화본이 제공되며 웹사이트에 보관될 예정입니다.
Inari Medical (NASDAQ: NARI) a annoncé qu'il organisera une réunion avec des analystes et des investisseurs pour discuter de l'étude PEERLESS suite à sa présentation lors des Séances des Essais Cliniques de Dernière Minute au Symposium Scientifique Annuel de la Thérapeutique Cardiovasculaire Transcatéthérisée (TCT) à Washington, D.C. La réunion est prévue pour le mardi 29 octobre 2024, à 11h00 heure du Pacifique / 14h00 heure de l'Est. Les parties intéressées peuvent accéder à l'événement en direct via la Section Événements du site des relations investisseurs d'Inari. Un replay sera disponible peu après l'événement et archivé sur le site.
Inari Medical (NASDAQ: NARI) hat angekündigt, ein Analysten- und Investorenmeeting abzuhalten, um die PEERLESS-Studie zu besprechen, die im Rahmen der Late-Breaking Clinical Trial Sessions beim Jährlichen Wissenschaftlichen Symposium der Transkatheter-Kardiovaskulären Therapeutik (TCT) in Washington, D.C. präsentiert wurde. Das Meeting ist für den Dienstag, den 29. Oktober 2024, um 11:00 Uhr Pazifischer Zeit / 14:00 Uhr Eastern Time angesetzt. Interessierte können die Live-Veranstaltung über den Event-Bereich der Investor-Relations-Website von Inari verfolgen. Eine Wiederholung wird kurz nach der Veranstaltung verfügbar sein und auf der Website archiviert.
- None.
- None.
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The analyst and investor meeting will be held on Tuesday, October 29, 2024 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.
Interested parties may access the live event by visiting the Events Section of the Inari investor relations website or by registering here. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.
Investor Contact:
Marissa Bych
Gilmartin Group LLC
IR@inarimedical.com
FAQ
When is Inari Medical's analyst and investor meeting for the PEERLESS study?
Where can I access the live event for Inari Medical's PEERLESS study discussion?
Will there be a replay available for Inari Medical's analyst and investor meeting?
What event will Inari Medical's PEERLESS study be presented at?
What is the stock symbol for Inari Medical?
